BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29906434)

  • 1. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
    Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
    J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
    Govers TM; Caba L; Resnick MJ
    J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
    Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
    BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion.
    Venderink W; Govers TM; de Rooij M; Fütterer JJ; Sedelaar JPM
    AJR Am J Roentgenol; 2017 May; 208(5):1058-1063. PubMed ID: 28225639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Faria R; Soares MO; Spackman E; Ahmed HU; Brown LC; Kaplan R; Emberton M; Sculpher MJ
    Eur Urol; 2018 Jan; 73(1):23-30. PubMed ID: 28935163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
    Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
    BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
    Getaneh AM; Heijnsdijk EA; de Koning HJ
    Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.
    Pahwa S; Schiltz NK; Ponsky LE; Lu Z; Griswold MA; Gulani V
    Radiology; 2017 Oct; 285(1):157-166. PubMed ID: 28514203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Men with Low-risk Prostate Cancer: A Cost-effectiveness Modeling Study.
    Patel S; Rongen JJ; Fütterer JJ; Boltyenkov A; Rovers MM
    Eur Urol Oncol; 2018 Dec; 1(6):476-483. PubMed ID: 31158091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prostate: decreasing cost-effectiveness of biopsy with advancing age.
    Gottlieb RH; Mooney C; Mushlin AI; Rubens DJ; Fultz PJ
    Invest Radiol; 1996 Feb; 31(2):84-90. PubMed ID: 8750443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
    Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
    JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.
    Govers TM; Resnick MJ; Rastinehad AR; Caba L; Groskopf J; van Criekinge W
    World J Urol; 2023 Jun; 41(6):1527-1532. PubMed ID: 37133554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
    Roth JA; Ramsey SD; Carlson JJ
    Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer.
    Cerantola Y; Dragomir A; Tanguay S; Bladou F; Aprikian A; Kassouf W
    Urol Oncol; 2016 Mar; 34(3):119.e1-9. PubMed ID: 26602178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.
    Wysock JS; Becher E; Persily J; Loeb S; Lepor H
    Urology; 2020 Jul; 141():119-124. PubMed ID: 32294481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy.
    Lotan Y; Haddad AQ; Costa DN; Pedrosa I; Rofsky NM; Roehrborn CG
    Urol Oncol; 2015 Jun; 33(6):266.e9-16. PubMed ID: 25858102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.